Table 2.
Effect of hAFSCs on renal tissue oxidative stress parameters (n=20/group)
| Group I negative control |
Group II cisplatin-treated |
Group III cisplatin+hAFSCs-treated |
Group VI Cisplatin+DMEM culture media treated |
||
|---|---|---|---|---|---|
| MDA (nmol/g tissue) | Day 4 | 14.6±1.61 | 66.5±2.83* | 34.7±6.72*,§ | 66.6±2.68*,# |
| Day 7 | 14.9±1.50 | 64.9±3.93*,‡ | 26.1±2.13*,§,‡ | 66.9±2.29*,# | |
| Day 11 | 15.4±1.63 | 35.5±3.33*,‡,† | 17.8±1.78§,‡,† | 34.8±2.84*,#,‡,† | |
| Day 30 | 15.1±1.62 | 30.1±4.61*,‡,† | 17.6±2.29§,‡,† | 28.1±1.58*,#,‡,†,• | |
| GSH (mmol/g tissue) | Day 4 | 5.40±0.25 | 0.26±0.03* | 0.76±0.02*,§ | 0.26±0.02*,# |
| Day 7 | 5.44±0.23 | 0.54±0.03*,‡ | 2.64±0.36*,§,‡ | 0.52±0.03*,#,‡ | |
| Day 11 | 5.55±0.17 | 1.49±0.33*,‡,† | 3.55±0.15*,§,‡,† | 1.32±0.30*,#,‡,† | |
| Day 30 | 5.32±0.31 | 1.92±0.03*,‡,† | 3.98±0.43*,§,‡,† | 1.91±0.05*,#,‡,†,• | |
| SOD (U/g tissue) | Day 4 | 20.36±1.70 | 2.98±0.19* | 6.93±0.42*,§ | 2.94±0.23*,# |
| Day 7 | 19.92±1.39 | 6.24±0.42*,‡ | 10.69±0.33*,§,‡ | 6.22±0.45*,#,‡ | |
| Day 11 | 19.88±1.40 | 9.98±0.32*,‡,† | 15.73±0.29*,§,‡,† | 10.0±0.25*,#,‡,† | |
| Day 30 | 20.22±1.70 | 15.3±0.36*,‡,†,• | 18.74±0.15§,‡,†,• | 15.6±0.49*,#,‡,†,• |
Significant difference compared to corresponding *control, §cisplatin group and #cisplatin+hAFSCs group.
Significant difference compared to intragroup ‡day 4, †day 7, •day 11 by one-way analysis of variance (ANOVA) followed by posthoc multiple comparisons (Scheffé test) at p≤0.05.